Document Detail

Intraperitoneal Use of Doxorubicin Drug-eluting Beads in Sheep: A Pilot Safety Study.
MedLine Citation:
PMID:  23225413     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: Intraperitoneal carcinmatosis and intra-abdominal tumour cell dissemination may occur with several tumour entities. At this final stage of the tumour disease, systemic chemotherapy remains only palliative and may be accompanied by severe side-effects. Alternatively, compartment-based therapy by intraperitoneal (i.p.) instillation of doxorubicin drug-eluting beads (dox-DEB) has been proposed. Here we investigated the safety, pharmacokinetics and side-effects of i.p. dox-DEB in a large animal trial.
MATERIALS AND METHODS: Ten black-headed meat-sheep received i.p. polyvinyl-alcohol-encapsulated doxorubicin. The plasma concentration of doxorubicin, blood count and laboratory findings were recorded and histological examination of the organs was performed.
RESULTS: After i.p. instillation, elevated serum levels of doxorubicin were obtained. After this initial phase, serum levels remained constant. Upon autopsy, no signs of systemic toxicity were detected. Beads remained within the peritoneal cavity and were not systemically distributed. However, we found significant local toxicity in five sheep, three of which died due to severe peritonitis.
CONCLUSION: Doxorubicin can be successfully targeted to the peritoneal cavity by bead encapsulation. Local toxic effects must be controlled in order to facilitate clinical utility.
Simon Binder; Andrew L Lewis; Ralf Jesenofsky; Michael Neumaier; Evelyn Jäger; Philipp Ströbel; J-Matthias Löhr; Michael Keese
Related Documents :
9775443 - Effects of new triphenylethylene platinum(ii) complexes on the interaction with phospha...
10699303 - In vivo monitoring of drugs using radiotracer techniques.
2935353 - Modifications of the lymphocyte transformation test in a case of drug-induced cholestat...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  5167-74     Citation Subset:  IM    
Clinic for Vascular and Endovascular Surgery, University Hospital Frankfurt, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Synergistic Anticancer Activity of Thiazolo[5,4-b]quinoline Derivative D3CLP in Combination with Cis...
Next Document:  DUOX Enzyme Activity Promotes AKT Signalling in Prostate Cancer Cells.